BEAM Stock Analysis: Buy, Sell, or Hold?
BEAM - Beam Therapeutics Inc. Common Stock
$29.76
1.37 (4.83%)
▲
5d:
+11.25%
30d:
+14.86%
90d:
+7.55%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Aug 20, 2026 at $28.28 · last confirmed Aug 20, 2026
Strength: 4.6/10
Get Alerted When BEAM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: BEAM shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: BEAM shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: BEAM is currently trading at $29.76, which is considered extended relative to its 30-day fair value range of $25.76 to $28.93.
Technical Outlook: Technically, BEAM is showing sideways momentum. The price is approaching resistance at $30.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.8% recently.
Market Sentiment: BEAM scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $52.15 (+75.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BEAM is showing sideways momentum. The price is approaching resistance at $30.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.8% recently.
Market Sentiment: BEAM scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $52.15 (+75.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$25.76 -
$28.93
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
31.6%
Protect Your Profits
Holding BEAM? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (23/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.8%)
- BULLISH: Trading 75.2% below Wall St target ($52.15)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$25.76 -
$28.93
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$25.71
Resistance Level
$30.50
Current Trend
Sideways
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.28
Wall Street Target
$52.15
(+75.2%)
Revenue Growth (YoY)
-94.2%
Profit Margin
-55.5%
Share & Embed Analysis
Last updated: August 22, 2026 4:26 PM ET
Data refreshes hourly during market hours. Next update: 5:26 PM
Data refreshes hourly during market hours. Next update: 5:26 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BEAM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Amy Simon
SELL
6700 shares
2026-04-01
Christine Bellon
SELL
5956 shares
2026-04-01
Giuseppe Ciaramella
SELL
11810 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$125 | 41 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 37 SELL |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$101 | 50 HOLD |
Advanced BEAM Option Strategies
Professional options setups generated by AI based on today's BEAM price and gamma walls.
